# A Phase 1 Study of Cizutamig in IgE Mediated Diseases

> **NCT07408869** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Candid Therapeutics** · enrollment: 20 (estimated)

## Conditions studied

- IgE-Mediated Hypersensitivity
- IgE Mediated Food Allergy
- IgE-Mediated Cow Milk Allergy

## Interventions

- **BIOLOGICAL:** Cizutamig

## Key facts

- **NCT ID:** NCT07408869
- **Lead sponsor:** Candid Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07408869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07408869, "A Phase 1 Study of Cizutamig in IgE Mediated Diseases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07408869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*